Fixed drug eruption: Topical provocation and subsequent phenomena

Journal of the College of Physicians and Surgeons Pakistan

Volumn 16, Issue 12, 2006, Pages 747-750

  Mahboob, Atiya ^a,e   Haroon, Tahir Saeed ^b   Iqbal, Zafar ^a   Iqbal, Farrukh ^a   Saleemi, Munir Akhtar ^c   Munir, Asma ^d  

^a Shaikh Zayed FPGMI ^*  (Pakistan)

^b KING EDWARD MEDICAL UNIVERSITY   (Pakistan)

^c MAYO HOSPITAL   (Pakistan)

^d KEMU   (Pakistan)

^e SHAIKH ZAYED HOSPITAL   (Pakistan)

Author keywords

5 drug ointment; Fixed drug eruption; Topical provocation

Indexed keywords

ACETYLSALICYLIC ACID; BELLADONNA ALKALOID; DAPSONE; DIPYRONE; ERYTHROMYCIN; LIQUID PARAFFIN; OXYTETRACYCLINE; PARACETAMOL; PHENOBARBITAL; PROPYPHENAZONE; SULFAMETHOXAZOLE; TINIDAZOLE; TRIMETHOPRIM;

ADOLESCENT; ADULT; AGED; ARTICLE; BURNING SENSATION; CHILD; CONTROLLED STUDY; ERYTHEMA; FEMALE; FIXED DRUG ERUPTION; HUMAN; HYPERPIGMENTATION; MAJOR CLINICAL STUDY; MALE; OINTMENT; PATCH TEST; PROVOCATION TEST; PRURITUS; QUASI EXPERIMENTAL STUDY; SKIN DEFECT;

ADMINISTRATION, ORAL; ADULT; DRUG ERUPTIONS; FEMALE; HUMANS; MALE; SKIN; SKIN TESTS;

EID: 34249109679     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Korkij W, Soltani K. Fixed drug eruption: a brief review. Arch Dermatol 1984; 120: 520-4.
2. Breathnach SM. Drug reactions. In: Champion RH, Burton JH, Ebing FJG, (edi). Rook/Wilkinson/Ebling text book of dermatology, 7th ed. London: Oxford Blackwell, 2004; 73: 28-9,172-3.
3. Browne SG. Fixed eruption in deeply pigmented subjects: clinical observations on 350 patients. Br Med J 1964; 2:1041-4.
4. Bork K. Undesirable cutaneous drug reactions. In: Bork K, (edi). Cutaneous side effects of drugs. Philadelphia: W.B Saunders, 1988: 98-108.
5. Kauppinen K, Stubb S. Fixed eruption: causative drug and challenge tests. Br J Dermatol 1985; 112: 575-8.
6. Sehgal VN, Gangwani OP. Fixed drug eruption: current concepts. Int J Dermatol 1987; 26: 67-74.
7. Thaukappan TP, Zachasiah J. Drug specific pattern in fixed drug eruption. Int J Dermatol 1991; 30: 867-70.
8. Savin JA. Current causes of fixed drug eruption. Br J Dermatol 1977;97:107-8.
9. Garcia JC, Torre F, Sanchez M, Martin JA, Canto G. Fixed drug eruption induced by Lidocaine and patch testing. J Invest Allergol Clin Immunol 1997; 7: 127-8.
10. Alanko K, Stubb S, Reitamo S. Topical provocation of fixed drug eruption. Br J Dermatol 1987; 116: 561-7.
11. Alanko K. Topical provocation of fixed drug eruption: a study of 30 patients. Contact Dermatitis 1994; 31: 25-7.
12. Lee AY. Topical provocation in 31 cases of fixed drug eruption: change of causative drugs in 10 years. Contact Dermatitis 1998; 38: 258-60.
13. Ozkaya-Bayazit E, Bayazit H, Ozarmagan G. Topical provocation in 27 cases of cotrimoxazole- induced fixed drug eruption. Contact Dermatitis 1999; 41: 185-9.
14. Lammintausta K, Kortekangas - Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol 2006; 154: 198.
15. Ozkaya, Bayazit E. Topical provocation in fixed drug eruption due to metamizole and naproxen. Clin Exp Dermatol 2004; 29: 419-22.
16. Tornero P, De Barrio M, Baeza ML. Herrero T. Cross - reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. Contact Dermatitis 2004; 51: 57-62.
17. Mahboob A, Saleemi MA. Topical provocation of fixed drug eruption. Ann KE Med Coll 1998; 4: 12-3.
18. Kauppinen K. Rational performance of drug challenge in cutaneous hypersensitivity. Semin Dermatol 1983; 2: 227.
19. Barbaud A, Trechot P, Reichert-Penetrat S, Granel F, Schmutz JL. The usefulness of patch testing on the previously most severely affected site in a cutaneous adverse drug reaction to tetrazepam. Contact Dermatitis 2001; 44: 259-60.
20. Oleage JM, Aguirre A, Gonzalex M, Diaz-Perez JL. Topical provocation of fixed drug eruption due to sulphamethoxazole. Contact Dermatitis 1993; 29:155.
21. Smola H, Kruppa A, Hunzelmann N, Krieg T, Scharffetter- Kochanek K. Identification of dimenhydrinate as the causative agent in fixed drug eruption using patch-testing in previously affected skin. Br J Dermatol 1998; 138: 920-1.
22. Short KA, Salisbury JR, Fuller LC. Fixed drug eruption following metronidazole therapy and the use of topical provocation testing in diagnosis. Clin Exp Dermatol 2002; 27: 464-6.
23. Prieto A, De Barrio M, Infante S, Torres A, Rubio M, Olalde S. Recurrent fixed drug eruption due to metronidazole elicited by patch test with tinidazole. Contact Dermatitis 2005; 53:169-70.
24. Al-Mutairi N, Al-Fouzan A, Nour-Eldin O. Fixed drug eruption due to influenza vaccine. J Cutan Med Surg 2004; 8: 16-8.
25. Bohm I, Medina J, Prieto P, Block W, Schild HH. Fixed drug eruption induced by an iodinated non-ionic X-ray contrast medium: a practical approach to identify the causative agent and to prevent its recurrence. Eur Radiol 2006; August 26:[Epub ahead of print]
26. Cuerda-Galindo E, Goday-Bujan JJ, Garcia-Silva JM, Martinez W, Verea-Hernando M, Fonseca E. Fixed drug eruption from piroxican. J Eur Acad Dermatol Venereol 2004; 18: 586-7.